Company Website: https://www.chromadex.com/
LOS ANGELES -- (Business Wire)

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2023 Investor Conference.

Mr. Fried and Mrs. Gerber will be participating in virtual one-on-one meetings throughout the event on Thursday, May 18, 2023.

To arrange a meeting with the ChromaDex management team, please contact Lytham Partners at 1x1@lythampartners.com, or register online by clicking the link here: ChromaDex Investor Meetings - Lytham Partners.

For additional information on ChromaDex, visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005158/en/

Contacts:

ChromaDex Media Contact:
Kendall Knysch, Director of Media Relations
310-388-6706 ext. 689
kendall.knysch@chromadex.com

ChromaDex Investor Relations Contact:
+1 (949) 356-1620
InvestorRelations@ChromaDex.com

Source: ChromaDex Corporation